ANN ARBOR, Mich.,May 3 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announces the following webcast:

What: Investor conference call to present an update on clinical development efforts related to critical limb ischemia (CLI). The event will also feature a Q&A session with Anthony J. Comerota, MD, FACS, FACC, director of the Jobst Vascular Center in Toledo, Ohio.

When: Monday, May 10, 2010 @ 1:00 pm (ET)

Where: http://www.investorcalendar.com/IC/CEPage.asp?ID=158215

How:

• For live Internet access, simply log on to the web at the address above.
• For phone access, interested parties should call toll-free (877) 407-9210 before the start of the call to register and identify themselves as registrants of the “Aastrom Conference Call”. Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8049.
• To download the podcast, simply log on to the web at the address above.

If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ until August 10, 2010. Through May 24, 2010, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 350255.

About Aastrom Biosciences

Aastrom Biosciences is developing autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company’s proprietary cell-processing technology enables the production of cellular therapies using a patient’s own bone marrow that can be delivered directly to damaged tissues. Aastrom has advanced this technology into late-stage clinical development and is conducting two Phase 2 clinical trials to treat dilated cardiomyopathy and a Phase 2b clinical trial to treat critical limb ischemia. For more information, please visit Aastrom’s website at www.aastrom.com.

SOURCE Aastrom Biosciences, Inc.